Anti-NMDA Receptor Encephalitis (NMDARE) is the most common form of autoimmune encephalitis, characterized by antibodies targeting the GluN1 (NR1) subunit of the [NMDA receptor](/entities/nmda-receptor) in the brain[@dalmau2007]. First described in 2007 by Dalmau and colleagues as a paraneoplastic disorder associated with ovarian teratomas, NMDARE has emerged as a treatable cause of subacute encephalitis affecting individuals of all ages, with a predominance in young women[@dalmau2007][@hughes2010].
The condition accounts for approximately 1-2 per 100,000 annual encephalitis cases and represents a paradigmatic example of antibody-mediated synaptic dysfunction[@granerod2010][@graus2016]. Unlike neurodegenerative diseases where neuronal loss is irreversible, NMDARE is characterized by reversible receptor internalization, explaining why aggressive immunotherapy can yield substantial recovery even in severe cases[@titulaer2013].
The pathogenic autoantibodies in NMDARE are predominantly IgG1 subclass antibodies that target the N-terminal domain (ATD) of the GluN1 (GRIN1) subunit of the [NMDA receptor](/entities/nmda-receptor)[@hughes2010]. Epitope mapping studies have identified the major binding site within amino acids 371-593 of the GluN1 extracellular domain, a region critical for receptor assembly and ligand binding[@chen2020].
Anti-NMDA Receptor Encephalitis (NMDARE) is the most common form of autoimmune encephalitis, characterized by antibodies targeting the GluN1 (NR1) subunit of the [NMDA receptor](/entities/nmda-receptor) in the brain[@dalmau2007]. First described in 2007 by Dalmau and colleagues as a paraneoplastic disorder associated with ovarian teratomas, NMDARE has emerged as a treatable cause of subacute encephalitis affecting individuals of all ages, with a predominance in young women[@dalmau2007][@hughes2010].
The condition accounts for approximately 1-2 per 100,000 annual encephalitis cases and represents a paradigmatic example of antibody-mediated synaptic dysfunction[@granerod2010][@graus2016]. Unlike neurodegenerative diseases where neuronal loss is irreversible, NMDARE is characterized by reversible receptor internalization, explaining why aggressive immunotherapy can yield substantial recovery even in severe cases[@titulaer2013].
The pathogenic autoantibodies in NMDARE are predominantly IgG1 subclass antibodies that target the N-terminal domain (ATD) of the GluN1 (GRIN1) subunit of the [NMDA receptor](/entities/nmda-receptor)[@hughes2010]. Epitope mapping studies have identified the major binding site within amino acids 371-593 of the GluN1 extracellular domain, a region critical for receptor assembly and ligand binding[@chen2020].
The antibodies recognize a conformational epitope that requires proper receptor tetramerization — isolated GluN1 subunits are not recognized, explaining why antibody binding requires intact surface receptors[@hughes2010]. This has therapeutic implications: antibodies can be displaced by competitive agonists (ifenprodil, D-serine) that bind nearby sites, providing rationale for pharmacologic intervention strategies[@chen2020].
Antibody binding triggers rapid, clathrin-dependent internalization of surface [NMDA receptors](/entities/nmda-receptor) through a process called capped-dependent endocytosis[@hughes2010][@chen2020]. Key kinetic features include:
The loss of surface [NMDA receptors](/entities/nmda-receptor) has profound effects on glutamatergic signaling and synaptic plasticity[@badran2022][@lee2019]:
The hippocampus is particularly vulnerable in NMDARE due to its high density of [NMDA receptors](/entities/nmda-receptor) and critical role in declarative memory formation[@lee2019]. Functional MRI studies in NMDARE patients demonstrate:
At the cellular level, hippocampal dysfunction in NMDARE involves[@badran2022][@lee2019]:
The antibody-mediated receptor loss propagates through memory circuits[@lee2019][@malter2023]:
Cerebrospinal fluid analysis in NMDARE reveals a characteristic inflammatory signature[@blumen2022][@byrne2019]:
| Biomarker | Elevation | Clinical Significance |
|-----------|-----------|----------------------|
| CXCL13 | Elevated (2-100x controls) | B-cell recruitment; diagnostic sensitivity 80%[@day2023] |
| IL-6 | Elevated (median 15 pg/mL) | Correlates with disease severity and CSF pleocytosis[@byrne2019] |
| TNF-alpha | Mildly elevated | Associated with blood-brain barrier dysfunction[@byrne2019] |
| Neurofilament light chain (NfL) | Elevated in severe cases | Marker of neuronal injury; prognostic indicator[@vande2020] |
| GFAP | Variable | Astrocyte activation marker; returns to normal with recovery[@blumen2022] |
| Oligoclonal bands | Positive in 60-70% | Indicates intrathecal IgG synthesis[@blumen2022] |
CXCL13, a B-cell chemokine, has emerged as a highly specific biomarker for NMDARE[@day2023][@byrne2019]:
Studies using dynamic contrast-enhanced MRI demonstrate that BBB disruption in NMDARE is not uniform[@byrne2019][@malter2023]:
PET studies using translocator protein (TSPO) ligands reveal widespread microglial activation in NMDARE[@malter2023]:
Many patients experience a prodromal phase lasting days to weeks[@dalmau2007][@graus2016]:
The classic progression of NMDARE follows distinct phases[@dalmau2007][@titulaer2013]:
The 2016 Graus criteria provide structured diagnostic guidance[@graus2016]:
First-line immunotherapy produces clinical improvement in approximately 80-90% of patients when initiated promptly[@titulaer2013][@iranirad2023]:
| Treatment | Protocol | Response Rate | Time to Improvement |
|-----------|----------|---------------|-------------------|
| Corticosteroids (methylprednisolone) | 1g IV daily x 3-5 days, then oral taper | 65-75% improvement | 1-2 weeks[@titulaer2013] |
| IV Immunoglobulin (IVIG) | 0.4 g/kg/day x 5 days | 60-70% improvement | 1-2 weeks[@iranirad2023] |
| Plasma Exchange | 5-7 exchanges over 10-14 days | 70-80% improvement | Days to 1 week[@titulaer2013] |
| Combination therapy | Steroids + IVIG or PLEX | 85-90% improvement | 1-2 weeks[@iranirad2023] |
The combination of corticosteroids plus IVIG or plasma exchange is associated with faster recovery and higher response rates than monotherapy[@titulaer2013][@iranirad2023].
In the 30-50% of patients with associated ovarian teratomas, tumor resection significantly improves outcomes[@dalmau2007][@titulaer2013]:
For patients with inadequate response to first-line therapy (approximately 20-25%)[@titulaer2013][@heeke2021]:
| Agent | Mechanism | Response Rate | Indications |
|-------|-----------|---------------|-------------|
| Rituximab (anti-CD20) | B-cell depletion | 70-80% improvement | Refractory symptoms after 2-4 weeks of first-line |
| Cyclophosphamide | Broad immunosuppression | 60-70% improvement | Severe refractory cases |
| Azathioprine/Mycophenolate | Maintenance therapy | Adjunctive benefit | Long-term relapse prevention |
Rituximab significantly reduces relapse rates from 15-20% to <5% and is increasingly used earlier in treatment protocols[@titulaer2013][@heeke2021].
Long-term follow-up studies demonstrate[@heeke2021][@titulaer2013]:
| Feature | Anti-NMDA Receptor | Anti-LGI1 | Anti-GABA_B Receptor |
|---------|-------------------|-----------|---------------------|
| Antibody target | GluN1 subunit of NMDA receptor | Leucine-rich glioma-inactivated 1 (LGI1) protein | GABA_B receptor subunits (GABA_B1/GABA_B2) |
| Primary antigen location | Synaptic NMDA receptor complex | Adhesion molecule linking presynaptic Kv1 to postsynaptic AMPAR | Postsynaptic GABA_B receptors |
| Age | Median 21 years; bimodal (young adults, older adults) | Median 64 years; predominantly older males | Median 55-65 years |
| Sex distribution | Female predominance (4:1) | Male predominance (2:1) | Male predominance (2:1) |
| Tumor association | Ovarian teratoma (30-50% of females); SCLC | Usually non-paraneoplastic | Small cell lung cancer (50-60%) |
| Classic presentation | Psychiatric symptoms, seizures, dyskinesias, dysautonomia | Faciobrachial dystonic seizures, limbic encephalitis | Limbic encephalitis, prominent seizures, ataxia |
| CSF pleocytosis | Common (60-80%) | Often normal | Common (60-70%) |
| MRI findings | Often normal; may show basal ganglia/temporal hyperintensities | Characteristic hippocampal T2/FLAIR hyperintensity | Temporal lobe abnormalities |
| First-line response | 80-90% improvement | 90-95% improvement | 75-85% improvement |
| Time to recovery | Weeks to months; can take 1-2 years | Often within weeks | Weeks to months |
| Cognitive outcomes | Variable; executive/memory deficits in 20-30% | Generally good; memory deficits may persist | Moderate; memory impairment common |
| Relapse rate | 10-20% (reduced to <5% with rituximab) | 10-15% | 10-20% |
| Mortality | 5-10% (higher if severe dysautonomia) | <2% | 10-15% (often related to underlying malignancy) |
Anti-NMDAR vs Anti-LGI1: The critical difference lies in pathogenic mechanism. Anti-NMDAR antibodies cause receptor internalization and functional loss of a major glutamate receptor subtype, disrupting synaptic plasticity broadly[@hughes2010][@chen2020]. Anti-LGI1 antibodies disrupt a synaptic adhesion complex without causing receptor internalization, explaining the predominantly limbic (memory) presentation and faster recovery[@nosadri2022].
Anti-NMDAR vs Anti-GABA_B R: Both target postsynaptic receptors with opposing effects on neuronal excitability. Anti-GABA_B R antibodies reduce inhibitory signaling, predisposing to severe seizures and status epilepticus. The paraneoplastic association with SCLC in anti-GABA_B R encephalitis also impacts prognosis through malignancy-related mortality[@nosadri2022].
Favorable[@titulaer2013][@heeke2021]:
While primarily an autoimmune condition, NMDARE provides important mechanistic insights relevant to neurodegenerative diseases[@badran2022][@malter2023]: